Clinical trialNCT00378131CompletedPhase 2Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

SponsorHelsinn Therapeutics (U.S.), IncEnrollment51Cancer Cachexia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with cachexia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

William Polvino, MD
Helsinn Therapeutics (U.S.), Inc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Palo Verde Hematology Oncology, Ltd.
Glendale, Arizona, United States
San Diego Pacific Oncology & Hematology Associates
Encinitas, California, United States
Sant P. Chawla, Md
Santa Monica, California, United States
Melbourne Internal Medicine Associates
Melbourne, Florida, United States
Southwest Oncology Associates
Lafayette, Louisiana, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Chesapeake Oncology Hematology Associates, Pa
Glen Burnie, Maryland, United States
Beth Israel Cancer Center
New York, New York, United States
Charleston Cancer Center
Charleston, South Carolina, United States
South Carolina Oncology Associates, Pa
Columbia, South Carolina, United States
South Carolina Cancer Specialists
Hilton Head Island, South Carolina, United States
University of Texas Medical Branch
Galveston, Texas, United States
Michael E. Debakey Va Medical Center
Houston, Texas, United States
Cancer Outreach Associates
Abingdon, Virginia, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Multicare Health System
Tacoma, Washington, United States
Northwest Medical Specialties
Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

RC-1291Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2006
Primary completion: 30 Apr 2007
Completion: 30 Apr 2007
Last update posted: 2 Sept 2013
Registered enrollment: 51
Registry id: NCT00378131

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.